THE PHARMACOKINETIC INTERACTION BETWEEN METHADONE AND THE INVESTIGATIONAL HCV PROTEASE INHIBITOR TELAPREVIR

被引：0
|
作者：
van Heeswijk, Rolf [1 ]
Vandevoorde, Ann [1 ]
Verboven, Peter [2 ]
Boogaerts, Griet [1 ]
De Paepe, Els [1 ]
van Solingen-Ristea, Rodica [1 ]
Beumont, Maria [1 ]
机构：
[1] Tibotec BVBA, Beerse, Belgium
[2] Janssen Res & Dev, Beerse, Belgium
来源：
SWISS MEDICAL WEEKLY | 2011年 / 141卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
H8
引用
收藏
页码：18S / 18S
页数：1
相关论文
共 50 条
  • [21] Pharmacokinetic Interaction Between the HCV Protease Inhibitor MK-5172 and Midazolam, Pitavastatin, and Atorvastatin in Healthy Volunteers
    Caro, Luzelena
    Talaty, Jennifer E.
    Guo, Zifang
    Reitmann, Christina
    Fraser, Iain P.
    Evers, Raymond
    Swearingen, Dennis
    Yeh, Wendy W.
    Butterton, Joan R.
    HEPATOLOGY, 2013, 58 : 437A - 438A
  • [22] Pharmacokinetic Interaction Between the HCV Protease Inhibitor MK-5172 and IV and Oral Rifampin in Healthy Volunteers
    Caro, Luzelena
    Talaty, Jennifer E.
    Guo, Zifang
    Butterfield, Kristin
    Prueksaritanont, Thomayant
    Rasmussen, Scott
    Fraser, Iain P.
    Yeh, Wendy W.
    Butterton, Joan R.
    HEPATOLOGY, 2013, 58 : 446A - 447A
  • [23] PHARMACOKINETIC INTERACTIONS BETWEEN THE HCV PROTEASE INHIBITOR BOCEPREVIR AND SIROLIMUS IN HEALTHY SUBJECTS
    Hulskotte, E. G.
    Feng, H. -P.
    Xuan, F.
    Lin, W.
    Zhu, Y.
    Rasmusen, S.
    Butterton, J. R.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S190 - S190
  • [24] The pharmacokinetic interaction between methadone and nelfinavir
    Clarke, S
    Mulcahy, F
    Bergin, C
    Tjia, J
    Brown, R
    Barry, M
    Back, DJ
    AIDS, 2000, 14 : S95 - S95
  • [25] Pharmacokinetic evaluation of the interaction between the HCV protease inhibitor boceprevir and the HMG-CoA reductase inhibitors atorvastatin and pravastatin
    Hulskotte, Ellen G.
    Gupta, Samir
    Xuan, Fengjuan
    Van Zutven, Marga
    O'Mara, Edward
    Wagner, John A.
    Butterton, Joan R.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 170 - 170
  • [26] Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir
    Burger, DM
    Hugen, PWH
    Kroon, FP
    Groeneveld, P
    Brinkman, K
    Foudraine, NA
    Sprenger, H
    Koopmans, PP
    Hekster, YA
    AIDS, 1998, 12 (15) : 2080 - 2082
  • [27] Evaluation of the Pharmacokinetic Interaction Between Doravirine and Methadone
    Khalilieh, Sauzanne
    Yee, Ka L.
    Sanchez, Rosa, I
    Vaynshteyn, Kate
    Fan, Li
    Searle, Shawn
    Bouhajib, Mohammed
    Iwamoto, Marian
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (02): : 151 - 161
  • [28] New and Efficient Synthesis of HCV NS3/4 A Protease Inhibitor Telaprevir
    Porala, Subbanarasimhulu
    Yerrabelly, Jayaprakash Rao
    Kasireddy, Venkateshwar Reddy
    Yerrabelly, Hemasri
    Ghojala, Venkat Reddy
    Rebelli, Pradeep
    CHEMISTRYSELECT, 2019, 4 (33): : 9523 - 9528
  • [29] PHARMACOKINETIC INTERACTION OF HCV NS3/4A PROTEASE INHIBITOR VANIPREVIR AND ROSUVASTATIN.
    Orito, Y.
    Iwasa, T.
    Uemura, N.
    Fujimoto, G.
    Yama, S.
    Gao, W.
    Caro, L.
    Fandozzi, C.
    Prucksaritanont, T.
    Anderson, M.
    Butterton, J.
    Hasegawa, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S24 - S25
  • [30] Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications
    Marra, Fiona
    zu Siederdissen, Christoph Hoener
    Khoo, Saye
    Back, David
    Schlag, Michael
    Ouwerkerk-Mahadevan, Sivi
    Bicer, Ceyhun
    Lonjon-Domanec, Isabelle
    Jessner, Wolfgang
    Beumont-Mauviel, Maria
    Kalmeijer, Ronald
    Cornberg, Markus
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (05) : 961 - 971
12345